sarpogrelate has been researched along with Arterial Obstructive Diseases in 4 studies
sarpogrelate: structure given in first source
| Excerpt | Relevance | Reference |
|---|---|---|
| " Forearm blood flow (FBF) and leg blood flow (LBF) responses to reactive hyperemia (RH) and sublingual administration of nitroglycerin (NTG) were measured using strain-gauge plethysmography." | 5.12 | Sarpogrelate hydrochloride, a selective 5-HT2A antagonist, improves vascular function in patients with peripheral arterial disease. ( Chayama, K; Goto, C; Higashi, Y; Miyazaki, M; Orihashi, K; Sanada, H; Sueda, T; Yoshizumi, M, 2007) |
| "Sarpogrelate is a selective 5-hydroxytryptamine (5-HT) receptor subtype 2A antagonist which blocks 5-HT induced platelet aggregation and proliferation of vascular smooth muscle cells." | 2.80 | Prospective Randomized Study of Sarpogrelate Versus Clopidogrel-based Dual Antiplatelet Therapies in Patients Undergoing Femoropopliteal Arterial Endovascular Interventions: Preliminary Results. ( Chen, YX; Gu, YQ; Hu, HJ; Li, XQ; Liu, CW; Song, XJ; Tian, HY; Wang, WD; Zhao, JC, 2015) |
| "Ticlopidine was significantly effective only at 100 mg/kg p." | 1.28 | Effect of (+/-)-2-(dimethylamino)-1-[[o-(m-methoxyphenethyl)phenoxy] methyl]ethyl hydrogen succinate on experimental models of peripheral obstructive disease. ( Hara, H; Kitajima, A; Shimada, H; Tamao, Y, 1991) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (25.00) | 18.2507 |
| 2000's | 2 (50.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, YX | 1 |
| Wang, WD | 1 |
| Song, XJ | 1 |
| Gu, YQ | 1 |
| Tian, HY | 1 |
| Hu, HJ | 1 |
| Zhao, JC | 1 |
| Li, XQ | 1 |
| Liu, CW | 1 |
| Nishihira, K | 1 |
| Yamashita, A | 1 |
| Tanaka, N | 1 |
| Kawamoto, R | 1 |
| Imamura, T | 1 |
| Yamamoto, R | 1 |
| Eto, T | 1 |
| Asada, Y | 1 |
| Miyazaki, M | 1 |
| Higashi, Y | 1 |
| Goto, C | 1 |
| Chayama, K | 1 |
| Yoshizumi, M | 1 |
| Sanada, H | 1 |
| Orihashi, K | 1 |
| Sueda, T | 1 |
| Hara, H | 1 |
| Shimada, H | 1 |
| Kitajima, A | 1 |
| Tamao, Y | 1 |
2 trials available for sarpogrelate and Arterial Obstructive Diseases
| Article | Year |
|---|---|
Prospective Randomized Study of Sarpogrelate Versus Clopidogrel-based Dual Antiplatelet Therapies in Patients Undergoing Femoropopliteal Arterial Endovascular Interventions: Preliminary Results.
Topics: Aged; Arterial Occlusive Diseases; Clopidogrel; Female; Fibrinolytic Agents; Humans; Kaplan-Meier Es | 2015 |
Sarpogrelate hydrochloride, a selective 5-HT2A antagonist, improves vascular function in patients with peripheral arterial disease.
Topics: Aged; Aged, 80 and over; Analysis of Variance; Arterial Occlusive Diseases; Biomarkers; Endothelium, | 2007 |
2 other studies available for sarpogrelate and Arterial Obstructive Diseases
| Article | Year |
|---|---|
Inhibition of 5-hydroxytryptamine receptor prevents occlusive thrombus formation on neointima of the rabbit femoral artery.
Topics: Animals; Arterial Occlusive Diseases; Catheterization; Disease Models, Animal; Femoral Artery; Fibri | 2006 |
Effect of (+/-)-2-(dimethylamino)-1-[[o-(m-methoxyphenethyl)phenoxy] methyl]ethyl hydrogen succinate on experimental models of peripheral obstructive disease.
Topics: Animals; Arterial Occlusive Diseases; Carrageenan; Fibrinolytic Agents; Infarction; Lauric Acids; Ma | 1991 |